Author response for "Efficacy and safety of once‐weekly semaglutide vs once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes ( <scp>SUSTAIN</scp> China): a 30‐week double‐blind, phase 3a, randomised trial"
crossref（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要